HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc. (HOOK): 9 pipeline candidates · ~7 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
7.0 months
D/E 0.80
Lead: Phase 2/Phase 3
9 candidates
N/A
N/A
A transparent, data-derived signal for HOOKIPA Pharma Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$14.2M
Cash
$40.5M
Quarterly Burn
$19.7M
Runway
7.0 mo
Revenue
$2.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| eseba-vec | Phase 2 |
| hb-200 | Phase 2 |
| hb-201 intravenous administration | Phase 1/Phase 2 |
| hb-201 iv | Phase 1/Phase 2 |
| hb-202/hb-201 alternating 2-vector therapy | Phase 2/Phase 3 |
| hb-400 | Preclinical |
| hb-500 | Phase 1 |
| hb-502 | Phase 1 |
| hb-700 | Preclinical |
Frequently asked questions
How many drug candidates are in HOOKIPA Pharma Inc.'s pipeline?
HOOKIPA Pharma Inc. (HOOK) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is HOOKIPA Pharma Inc.'s lead drug candidate?
HOOKIPA Pharma Inc.'s most advanced tracked candidate is eseba-vec (Phase 2) for Human Papillomavirus 16-positive (HPV16+) head and neck cancers.
What is HOOKIPA Pharma Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, HOOKIPA Pharma Inc. has approximately 7.0 months of cash runway.
What is HOOKIPA Pharma Inc.'s market capitalization?
HOOKIPA Pharma Inc.'s market capitalization is approximately $14.2M.
Who is the CEO of HOOKIPA Pharma Inc.?
Dr. Malte Peters M.D. is the chief executive officer of HOOKIPA Pharma Inc. (HOOK).
Get the full picture on HOOKIPA Pharma Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.